Technical Data
6-ECDCA (6alpha-Ethyl-chenodeoxycholic acid, 6-alpha-ECDC, Obeticholic acid, INT-747)
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Potent and selective FXR agonist (EC50= 99nM). Induces SHP in HSCs to suppress TIMP-1 expression. Apoptosis inducer. Protects against liver fibrosis development in rat in vivo. Displays anticholeretic activity in rat in vivo. Promotes preadipocyte differentiation. Regulates adipogenesis and insulin signaling in vivo. Inhibits vascular smooth muscle cell inflammation and migration.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:

Molecular Formula:

Molecular Weight:
Purity: >95% (HPLC)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
6r-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity: R. Pellicciari, et al.; J. Med. Chem. 45, 3569 (2002)
A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 314, 584 (2005)
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 313, 604 (2005)
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo: G. Rizzo, et al.; Mol. Pharmacol. 70, 1164 (2006)
Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration: Y.T. Li, et al.; Arterioscler. Thromb. Vasc. Biol. 27, 2606 (2007)

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.